The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.
Saved in:
| Title: | The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial. |
|---|---|
| Authors: | Block MS; Mayo Clinic Cancer Center, Rochester, MN, USA., Clubb JHA; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Mäenpää J; Docrates Cancer Center, Helsinki, Finland.; Tampere University, Faculty of Medicine and Medical Technology, Tampere, Finland., Pakola S; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Quixabeira DCA; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Kudling T; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Jirovec E; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Haybout L; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., van der Heijden M; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Zahraoui S; TILT Biotherapeutics Ltd, Helsinki, Finland., Grönberg-Vähä-Koskela S; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Raatikainen S; TILT Biotherapeutics Ltd, Helsinki, Finland., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Basnet S; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Ojala N; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Pellinen T; Digital Microscopy and Molecular Pathology Unit, Institute for Molecular Medicine Finland, Helsinki, Finland., Hemmes A; Digital Microscopy and Molecular Pathology Unit, Institute for Molecular Medicine Finland, Helsinki, Finland., Välimäki K; Digital Microscopy and Molecular Pathology Unit, Institute for Molecular Medicine Finland, Helsinki, Finland., Pasanen A; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Alanko T; Docrates Cancer Center, Helsinki, Finland., Adamo D; Mayo Clinic Cancer Center, Rochester, MN, USA., Ramadan S; Docrates Cancer Center, Helsinki, Finland., Sormunen J; Docrates Cancer Center, Helsinki, Finland., Kononen J; Docrates Cancer Center, Helsinki, Finland., Cohen JW; Merck & Co. Inc., Rahway, NJ, USA., Chisamore MJ; Merck & Co. Inc., Rahway, NJ, USA., Goldfinch J; TILT Biotherapeutics Ltd, Helsinki, Finland., Sorsa S; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Havunen R; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Kistler C; TILT Biotherapeutics Ltd, Helsinki, Finland., Kalervo A; TILT Biotherapeutics Ltd, Helsinki, Finland., Cervera-Carrascon V; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Dos Santos JM; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Hemminki A; TILT Biotherapeutics Ltd, Helsinki, Finland. akseli.hemminki@helsinki.fi.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland. akseli.hemminki@helsinki.fi.; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland. akseli.hemminki@helsinki.fi. |
| Source: | Nature communications [Nat Commun] 2025 Feb 05; Vol. 16 (1), pp. 1381. Date of Electronic Publication: 2025 Feb 05. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Multicenter Study |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-025-56482-w |
